NDAORALTABLET
Approved
Apr 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
2
Mechanism of Action
(IBAT). It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum . Pruritus is a common symptom in patients with ALGS or PFIC and the pathophysiology of pruritus in patients with ALGS or PFIC is not completely understood. Although the complete mechanism by…
Clinical Trials (2)
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)
Started Sep 2025
100 enrolled
Alagille Syndrome
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
Started Sep 2023
70 enrolled
Alagille SyndromeProgressive Familial Intrahepatic Cholestasis
Loss of Exclusivity
LOE Date
Oct 5, 2043
214 months away
Patent Expiry
Oct 5, 2043
Exclusivity Expiry
Mar 13, 2027